Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000164412 | SCV000215049 | uncertain significance | Hereditary cancer-predisposing syndrome | 2016-09-22 | criteria provided, single submitter | clinical testing | The c.*2dupC variant is located in the 3' untranslated region (3’UTR) of the CHEK2 gene. This variant results from the duplication of C two nucleotides after the termination codon of the CHEK2 gene. This alteration occurs within the non-coding region of the gene and may not interfere with gene function; however, since supporting evidence is limited at this time, the clinical significance of this variant remains unclear. |
Color Diagnostics, |
RCV000164412 | SCV000902792 | likely benign | Hereditary cancer-predisposing syndrome | 2016-10-26 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001193682 | SCV001362694 | uncertain significance | not specified | 2021-09-16 | criteria provided, single submitter | clinical testing | Variant summary: CHEK2 c.*2dupC is located in the untranslated mRNA region downstream of the termination codon. The variant allele was found at a frequency of 3.9e-05 in 233634 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.*2dupC has been reported in the literature in a study looking at prevalence of genetic susceptibility for breast and ovarian cancer in a non-cancer related cohort (Karemer_2019). This report does not provide an unequivocal conclusion about association of the variant with Hereditary Breast and Ovarian Cancer. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two ClinVar submissions (evaluation after 2014) cite the variant once as likely benign and once as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. |
Gene |
RCV001675647 | SCV001895672 | benign | not provided | 2015-07-02 | criteria provided, single submitter | clinical testing | |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV001675647 | SCV004221710 | uncertain significance | not provided | 2023-02-03 | criteria provided, single submitter | clinical testing | The frequency of this variant in the general population, 0.000064 (8/124118 chromosomes, http://gnomad.broadinstitute.org), is uninformative in assessment of its pathogenicity. In the published literature, the variant has been reported in an individual with lung cancer (PMID: 33594163 (2021)). Based on the available information, we are unable to determine the clinical significance of this variant. |
Mayo Clinic Laboratories, |
RCV001675647 | SCV005410213 | uncertain significance | not provided | 2024-01-04 | criteria provided, single submitter | clinical testing | BP4 |